Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 140

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 140
---
38 |
| Business earnings per share (non-IFRS) (€)                                                                                            |    7.12 |    7.25 |    8.07 |

(a) For 2024, this line corresponds to (i) an impairment loss of €640 million in connection with various research and development projects – including a €239 million loss resulting from the decision taken in February 2025 to discontinue a phase 3 clinical study investigating of a vaccine candidate to prevent invasive E.coli disease - and (ii) an impairment reversal of €392 million recognized in connection with the disposals of the ProXTen technology platform and of Enjaymo, a commercialized product. For 2023, this amount mainly comprises an impairment loss of €833 million, reflecting the impact of the strategic decision to de-prioritize certain R&D programs, in particular those related to the NK Cell and ProXTen technology platforms. For 2022, this line includes a reversal of €2,154 million on Eloctate franchise products following FDA approval of ALTUVIIIO on February 22, 2023, partly offset by an impairment loss of €1,586 million on intangible assets relating to SAR444245 (non-alpha interleukin-2) based on revised cash flow projections reflecting unfavorable developments in the launch schedule in key indications. (b) This line includes an impact attributable to non-controlling interests, related to a remeasurement of contingent consideration within a subsidiary of Sanofi: €31 million expense in 2024, not material in 2023 and €80 million expense in 2022. (c) Other gains and losses, and litigation for 2024 represent a charge of € 470 millio n, mainly comprising a provision recognized in respect of the litigation related to Plavix (clopidogrel) in the US state of Hawaii (see Note D.22.) (d) This line corresponds to the financial expense arising from remeasurement of the financial liability recognized in the balance sheet to reflect estimated future royalties on sales of Beyfortus in the United States. (e) This line includes the share of profits/losses arising from the equity-accounted investment in EUROAPI, including an impairment loss taken against the equity interests based on the quoted market price: €2.88 as of December 31, 2024 and € 5.73 as of December 31, 2023. (f) Corresponds to the reconciliation between basic earnings per Share